These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 6487495)

  • 21. Disposition of antipyrine in patients with extensive metastatic liver disease.
    Robertz-Vaupel GM; Lindecken KD; Edeki T; Funke C; Belwon S; Dengler HJ
    Eur J Clin Pharmacol; 1992; 42(5):465-9. PubMed ID: 1606991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of isoniazid and oral contraceptive steroids on antipyrine oxidation and acetaminophen conjugation.
    Ochs HR; Greenblatt DJ; Verburg-Ochs B; Abernethy DR; Knüchel M
    Pharmacology; 1984; 28(4):188-95. PubMed ID: 6728897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione.
    Ohashi K; Sakamoto K; Sudo T; Tateishi T; Harada K; Fujimura A; Ebihara A; Tanaka E
    J Clin Pharmacol; 1991 Dec; 31(12):1132-6. PubMed ID: 1761736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of single and multiple doses of sulphinpyrazone on antipyrine metabolism and urinary excretion of 6-beta-hydroxycortisol.
    Staiger C; Schlicht F; Walter E; Gundert-Remy U; Hildebrandt R; de Vries J; Wang NS; Harenberg J; Weber E
    Eur J Clin Pharmacol; 1983; 25(6):797-801. PubMed ID: 6141054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of sex on antipyrine metabolism in cattle at different ages.
    Janus K; Antoszek J
    J Vet Pharmacol Ther; 1999 Jun; 22(3):163-9. PubMed ID: 10447826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma concentration-response relationship for cimetidine inhibition of drug metabolism in the rat.
    Adedoyin A; Aarons L; Houston JB
    Drug Metab Dispos; 1987; 15(1):127-32. PubMed ID: 2881749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human metabolism of antipyrine labelled with 14C in the pyrazolone ring or in the N-methyl group.
    Uchino H; Inaba T; Kalow W
    Xenobiotica; 1983 Mar; 13(3):155-62. PubMed ID: 6613161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipyrine clearance and metabolism in patients with psoriasis.
    Kubota K; Ishizaki T; Chiba K; Takagi A; Nakagawa A; Nakamura K
    Br J Clin Pharmacol; 1986 Oct; 22(4):455-62. PubMed ID: 3768257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antipyrine metabolism in acute hepatic porphyria in relapse and remission.
    Birnie GG; McColl KE; Thompson GG; Moore MR; Goldberg A; Brodie MJ
    Br J Clin Pharmacol; 1987 Mar; 23(3):358-61. PubMed ID: 3567053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases].
    Ohnhaus EE; Münch U; Meier J
    Schweiz Med Wochenschr; 1976 Dec; 106(49):1748-50. PubMed ID: 1013699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of sex and oral contraceptive steroids on antipyrine metabolite formation.
    Teunissen MW; Srivastava AK; Breimer DD
    Clin Pharmacol Ther; 1982 Aug; 32(2):240-6. PubMed ID: 7094512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antipyrine clearance and metabolite formation: the influence of liver volume and smoking.
    Spoelstra P; Teunissen MW; Janssens AR; Weeda B; van Duijn W; Koch CW; Breimer DD
    Eur J Clin Invest; 1986 Aug; 16(4):321-7. PubMed ID: 3093244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elimination of antipyrine and its metabolites in interferon treated hepatitis C.
    Sieck JO; el-Yazigi A; Ali H; Døssing M; Saour J; Raines DA; Ernst P
    Hum Exp Toxicol; 1994 Sep; 13(9):598-601. PubMed ID: 7986571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine.
    Shaw PN; Houston JB; Rowland M; Hopkins K; Thiercelin JF; Morselli PL
    Br J Clin Pharmacol; 1985 Dec; 20(6):611-8. PubMed ID: 4091993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disposition of antipyrine and phenytoin correlated with age and liver volume in man.
    Bach B; Hansen JM; Kampmann JP; Rasmussen SN; Skovsted L
    Clin Pharmacokinet; 1981; 6(5):389-96. PubMed ID: 7333060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impairment of drug elimination in patients with liver disease.
    Narang AP; Datta DV; Mathur VS
    Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):28-32. PubMed ID: 3988389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between antipyrine metabolism and acetylation phenotype in health and chronic liver diseases.
    el-Yazigi A; Raines DA; Wahab FA; Sieck JO; Ernst P; Ali H; Dossing M
    J Clin Pharmacol; 1995 Jun; 35(6):615-21. PubMed ID: 7665722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antipyrine kinetics in liver disease and liver transplantation.
    Mehta MU; Venkataramanan R; Burckart GJ; Ptachcinski RJ; Yang SL; Gray JA; Van Thiel DH; Starzl TE
    Clin Pharmacol Ther; 1986 Apr; 39(4):372-7. PubMed ID: 3514052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in metabolism and urinary excretion of antipyrine induced by aerobic conditioning.
    Villa JG; Bayon JE; González-Gallego J
    J Sports Med Phys Fitness; 1999 Sep; 39(3):197-201. PubMed ID: 10573660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between the metabolism of antipyrine, hexobarbital and theophylline in patients with liver disease as assessed by a 'cocktail' approach.
    Schellens JH; Janssens AR; van der Wart JH; van der Velde EA; Breimer DD
    Eur J Clin Invest; 1989 Oct; 19(5):472-9. PubMed ID: 2511024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.